Novel biomarkers such as isocitrate dehydrogenase 1 gene (IDH1) and O6-methylguanine-DNA-methyltransferase (MGMT) gene methylation status have been proposed as useful tool to predict prognosis and survival of glioma patients [11]. Here, IDH1 is linked to central nervous system cancer.